Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity

Opeyemi Stella Ademowo, Praveen Sharma, Paul Cockwell, Ana Reis, Iain L. Chapple, Helen R. Griffiths, Irundika Hk. Dias

Research output: Contribution to journalArticle

Abstract

Individuals with chronic kidney disease (CKD) and periodontitis as a co-morbidity have a higher mortality rate than individuals with CKD and no periodontitis. The inflammatory burden associated with both diseases contributes to an increased risk of cardiovascular and all-cause mortality. We previously demonstrated that periodontitis is associated with increasing circulating markers of inflammation and oxidative stress. We propose that inflammatory oxidised phosphocholines may contribute to the increased risk of cardiovascular disease in patients with CKD. However, the analysis of oxidised phospholipids has been limited by a lack of authentic standards for absolute quantification. Here, we have developed a comprehensive quantification liquid chromatography-mass spectrometry-based multiple reaction monitoring method for oxidised phospholipids (including some without available authentic species) that enables us to simultaneously measure twelve oxidised phosphatidylcholine species with high levels of sensitivity and specificity. The standard curves for commercial standards 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC); 1-palmitoyl-2-(9′-oxo-nonanoyl)-sn-glycero-3-phosphatidylcholine (PONPC), 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphatidylcholine (PAzPC) and 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphatidylcholine (POVPC), were linear with a correlation coefficient greater than 0.99 for all analytes. The method is reproducible, with intra- and inter-day precision <15%, and accuracy within ±5% of nominal values for all analytes. This method has been successfully applied to investigate oxidised phosphatidylcholine in plasma from CKD patients with and without chronic periodontitis and the data that was obtained has been compared to plasma from healthy controls. Comparative analysis demonstrates altered chain fragmented phosphatidylcholine profiles in the plasma samples of patients with CKD and periodontitis as a co-morbidity compared to healthy controls.

Original languageEnglish
Pages (from-to)130-138
Number of pages9
JournalFree Radical Biology and Medicine
Volume146
Early online date20 Oct 2019
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Chronic Periodontitis
Phosphatidylcholines
Chronic Renal Insufficiency
Morbidity
Plasmas
Periodontitis
Phospholipids
Oxidative stress
Phosphorylcholine
Mortality
Liquid chromatography
Liquid Chromatography
Mass spectrometry
Mass Spectrometry
Oxidative Stress
Cardiovascular Diseases
Inflammation
Sensitivity and Specificity
Monitoring

Bibliographical note

© 2019, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/


Funding: Kidney Research UK (PDF3/2014), Alzheimer's Research UK network grant 2017, Portuguese National Funds (NORTE-01-0145-FEDER-000011), JABBS foundation, doctoral research fellowship grant by the National Institute of Health Research (NIHR), UK (grant reference: DRF-2014-07-109).

Keywords

  • CKD
  • MRM-LC/MS
  • Oxidative stress
  • Oxidised phospholipids
  • Periodontitis

Cite this

Ademowo, Opeyemi Stella ; Sharma, Praveen ; Cockwell, Paul ; Reis, Ana ; Chapple, Iain L. ; Griffiths, Helen R. ; Dias, Irundika Hk. / Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity. In: Free Radical Biology and Medicine. 2020 ; Vol. 146. pp. 130-138.
@article{ab4da43a13574dc3887a40ebce211e49,
title = "Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity",
abstract = "Individuals with chronic kidney disease (CKD) and periodontitis as a co-morbidity have a higher mortality rate than individuals with CKD and no periodontitis. The inflammatory burden associated with both diseases contributes to an increased risk of cardiovascular and all-cause mortality. We previously demonstrated that periodontitis is associated with increasing circulating markers of inflammation and oxidative stress. We propose that inflammatory oxidised phosphocholines may contribute to the increased risk of cardiovascular disease in patients with CKD. However, the analysis of oxidised phospholipids has been limited by a lack of authentic standards for absolute quantification. Here, we have developed a comprehensive quantification liquid chromatography-mass spectrometry-based multiple reaction monitoring method for oxidised phospholipids (including some without available authentic species) that enables us to simultaneously measure twelve oxidised phosphatidylcholine species with high levels of sensitivity and specificity. The standard curves for commercial standards 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC); 1-palmitoyl-2-(9′-oxo-nonanoyl)-sn-glycero-3-phosphatidylcholine (PONPC), 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphatidylcholine (PAzPC) and 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphatidylcholine (POVPC), were linear with a correlation coefficient greater than 0.99 for all analytes. The method is reproducible, with intra- and inter-day precision <15{\%}, and accuracy within ±5{\%} of nominal values for all analytes. This method has been successfully applied to investigate oxidised phosphatidylcholine in plasma from CKD patients with and without chronic periodontitis and the data that was obtained has been compared to plasma from healthy controls. Comparative analysis demonstrates altered chain fragmented phosphatidylcholine profiles in the plasma samples of patients with CKD and periodontitis as a co-morbidity compared to healthy controls.",
keywords = "CKD, MRM-LC/MS, Oxidative stress, Oxidised phospholipids, Periodontitis",
author = "Ademowo, {Opeyemi Stella} and Praveen Sharma and Paul Cockwell and Ana Reis and Chapple, {Iain L.} and Griffiths, {Helen R.} and Dias, {Irundika Hk.}",
note = "{\circledC} 2019, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: Kidney Research UK (PDF3/2014), Alzheimer's Research UK network grant 2017, Portuguese National Funds (NORTE-01-0145-FEDER-000011), JABBS foundation, doctoral research fellowship grant by the National Institute of Health Research (NIHR), UK (grant reference: DRF-2014-07-109).",
year = "2020",
month = "1",
doi = "10.1016/j.freeradbiomed.2019.10.012",
language = "English",
volume = "146",
pages = "130--138",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier",

}

Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity. / Ademowo, Opeyemi Stella; Sharma, Praveen; Cockwell, Paul; Reis, Ana; Chapple, Iain L.; Griffiths, Helen R.; Dias, Irundika Hk.

In: Free Radical Biology and Medicine, Vol. 146, 01.2020, p. 130-138.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity

AU - Ademowo, Opeyemi Stella

AU - Sharma, Praveen

AU - Cockwell, Paul

AU - Reis, Ana

AU - Chapple, Iain L.

AU - Griffiths, Helen R.

AU - Dias, Irundika Hk.

N1 - © 2019, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: Kidney Research UK (PDF3/2014), Alzheimer's Research UK network grant 2017, Portuguese National Funds (NORTE-01-0145-FEDER-000011), JABBS foundation, doctoral research fellowship grant by the National Institute of Health Research (NIHR), UK (grant reference: DRF-2014-07-109).

PY - 2020/1

Y1 - 2020/1

N2 - Individuals with chronic kidney disease (CKD) and periodontitis as a co-morbidity have a higher mortality rate than individuals with CKD and no periodontitis. The inflammatory burden associated with both diseases contributes to an increased risk of cardiovascular and all-cause mortality. We previously demonstrated that periodontitis is associated with increasing circulating markers of inflammation and oxidative stress. We propose that inflammatory oxidised phosphocholines may contribute to the increased risk of cardiovascular disease in patients with CKD. However, the analysis of oxidised phospholipids has been limited by a lack of authentic standards for absolute quantification. Here, we have developed a comprehensive quantification liquid chromatography-mass spectrometry-based multiple reaction monitoring method for oxidised phospholipids (including some without available authentic species) that enables us to simultaneously measure twelve oxidised phosphatidylcholine species with high levels of sensitivity and specificity. The standard curves for commercial standards 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC); 1-palmitoyl-2-(9′-oxo-nonanoyl)-sn-glycero-3-phosphatidylcholine (PONPC), 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphatidylcholine (PAzPC) and 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphatidylcholine (POVPC), were linear with a correlation coefficient greater than 0.99 for all analytes. The method is reproducible, with intra- and inter-day precision <15%, and accuracy within ±5% of nominal values for all analytes. This method has been successfully applied to investigate oxidised phosphatidylcholine in plasma from CKD patients with and without chronic periodontitis and the data that was obtained has been compared to plasma from healthy controls. Comparative analysis demonstrates altered chain fragmented phosphatidylcholine profiles in the plasma samples of patients with CKD and periodontitis as a co-morbidity compared to healthy controls.

AB - Individuals with chronic kidney disease (CKD) and periodontitis as a co-morbidity have a higher mortality rate than individuals with CKD and no periodontitis. The inflammatory burden associated with both diseases contributes to an increased risk of cardiovascular and all-cause mortality. We previously demonstrated that periodontitis is associated with increasing circulating markers of inflammation and oxidative stress. We propose that inflammatory oxidised phosphocholines may contribute to the increased risk of cardiovascular disease in patients with CKD. However, the analysis of oxidised phospholipids has been limited by a lack of authentic standards for absolute quantification. Here, we have developed a comprehensive quantification liquid chromatography-mass spectrometry-based multiple reaction monitoring method for oxidised phospholipids (including some without available authentic species) that enables us to simultaneously measure twelve oxidised phosphatidylcholine species with high levels of sensitivity and specificity. The standard curves for commercial standards 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC); 1-palmitoyl-2-(9′-oxo-nonanoyl)-sn-glycero-3-phosphatidylcholine (PONPC), 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphatidylcholine (PAzPC) and 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphatidylcholine (POVPC), were linear with a correlation coefficient greater than 0.99 for all analytes. The method is reproducible, with intra- and inter-day precision <15%, and accuracy within ±5% of nominal values for all analytes. This method has been successfully applied to investigate oxidised phosphatidylcholine in plasma from CKD patients with and without chronic periodontitis and the data that was obtained has been compared to plasma from healthy controls. Comparative analysis demonstrates altered chain fragmented phosphatidylcholine profiles in the plasma samples of patients with CKD and periodontitis as a co-morbidity compared to healthy controls.

KW - CKD

KW - MRM-LC/MS

KW - Oxidative stress

KW - Oxidised phospholipids

KW - Periodontitis

UR - https://linkinghub.elsevier.com/retrieve/pii/S0891584919311037

UR - http://www.scopus.com/inward/record.url?scp=85076566496&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2019.10.012

DO - 10.1016/j.freeradbiomed.2019.10.012

M3 - Article

VL - 146

SP - 130

EP - 138

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

ER -